This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Stocks at Record: Buy 5 Top Cheap ETFs With High Potential
by Sanghamitra Saha
Wall Street has rallied hard this year on vaccine distribution, a prolonged period of easy money policy, fiscal stimulus and stronger-than-expected earnings.
ETF Asset Report of July
by Sanghamitra Saha
The month of July was moderately upbeat for the S&P500. The month marked the sixth straight monthly gains.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
5 Top-Ranked ETF Winners of July With More Upside Potential
by Sweta Killa
The month of July was marked with huge volatility for Wall Street.
The Zacks Analyst Blog Highlights: FDIS, KRE, DGRO, FMAT and XLV
by Zacks Equity Research
The Zacks Analyst Blog Highlights: FDIS, KRE, DGRO, FMAT and XLV
5 Top-Ranked ETFs Looking Good After a Decent July
by Sweta Jaiswal, FRM
Here we discuss some top-ranked ETFs that seem like a good addition to the portfolio considering the present market scenario largely dominated by delta variant concerns.
5 Hot Equity ETFs of Last Week to Sizzle on Solid Earnings
by Sweta Killa
Despite the outflows, some U.S. equity ETFs topped the creation list last week on earnings optimism.
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
JNJ Beats on Q2 Earnings, Ups View: ETFs to Buy
by Sweta Killa
The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.
UnitedHealth's Solid Q2 Earnings Put These ETFs in Focus
by Sweta Killa
UnitedHealth reported better-than-expected second-quarter 2021 results, breezing past the Zacks Consensus Estimate for both earnings and revenues.